Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06096077 · ClinicalTrials.gov registry record
Evaluation of Tranexamic Acid for Angiotensin-converting Enzyme Inhibitor-induced Angioedema in the Emergency Department
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 50
- Enrollment target
NCT06096077 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 50 participants.
The verdict
NCT06096077 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
Angiotensin-converting enzyme inhibitor ACEi induced angioedema ACEi-AE is defined as physical swelling of the deep skin layers or mucous membranes due to increased vascular permeability and leakage of fluid into the interstitial space caused while taking an ACEi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-11-30 |
| Est. Completion | 2023-08-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06096077
The ClinicalTrials.gov registry entry for NCT06096077 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Methodist Health System, which has 125 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06096077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06096077 about?
NCT06096077 is a clinical study titled "Evaluation of Tranexamic Acid for Angiotensin-converting Enzyme Inhibitor-induced Angioedema in the Emergency Department". Angiotensin-converting enzyme inhibitor ACEi induced angioedema ACEi-AE is defined as physical swelling of the deep skin layers or mucous membranes due to increased vascular permeability and leakage of fluid into the interstitial space caused while taking an ACEi
What is the current status of trial NCT06096077?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2022-11-30. Estimated completion is 2023-08-23.
Who is sponsoring clinical trial NCT06096077?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.